Clinical trial
Erlotinib in Treating Patients With Recurrent Glioblastoma Multiforme or…
NCT00387894 · Michael Prados, Other · Terminated
Key facts
| NCT number | NCT00387894 |
|---|---|
| Title | Erlotinib in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma |
| Official title | Phase-2 Study of Tarceva in Patients With Recurrent EGFR Positive and Phosphatase and Tensin Homolog (PTEN) Wild Type Glioblastoma Multiforme and Gliosarcoma |
| Lead sponsor | Michael Prados, Other |
| Collaborators | National Cancer Institute (NCI) NIH Genentech, Inc. Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Adult Brain Tumors |
| Intervention type | Drug |
| Interventions | erlotinib hydrochloride |
| Enrollment | 6 |
| Start date | Jan 1, 2007 |
| Primary completion | Mar 1, 2009 |
| Completion | Mar 1, 2009 |
| First posted | Oct 13, 2006 |
| Last update posted | Jun 4, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: